The latest announcement is out from Neurogene (NGNE).
Neurogene Inc. recently shared promising initial safety results from its Phase 1/2 clinical trial for a gene therapy targeting Rett syndrome. At the American Society for Gene and Cell Therapy Annual Meeting, they revealed that their NGN-401 treatment was generally well tolerated by patients over various follow-up periods. This positive announcement indicates a significant step forward in the development of gene therapies for genetic disorders, capturing the interest of investors and individuals keen on medical advancements in the stock market.
Learn more about NGNE stock on TipRanks’ Stock Analysis page.
